摘要
沙芬酰胺是一种单胺氧化酶-B(MAO-B)抑制剂,可辅助左旋多巴或卡比多巴用于治疗帕金森病患者"开-关"现象的"关"期("off"episodes)。本文对其药理作用、药动学、药物相互作用、临床评价、安全性、用法用量等进行综述。
Safinamide is a monoamine oxidase type B（MAO-B） inhibitor indicated as adjunctive treatment to levodopa or cabidopa in patients with Parkinson＇s disease（PD） experiencing ＂off＂ episodes. In this paper, the pharmacological effects, pharmacokinetics, drug interactions, clinical evaluation, safety, usage, and dosage of safinamide were reviewed.
作者
张舒
陈晴
胡咏川
刘蕾
ZHANG Shu;CHEN Qing;HU Yong-chuan;LIU Lei(Department of Pharmacy, Assessment of Clinical Drugs＇ Risk and Individual Application Key Laboratory, Beijing Hospital, National Center of Gerontology, Beijing 100730, China;School of Pharmaceutical Science, Peking University Health Science Center, Beijing 100191, China)
出处
《临床药物治疗杂志》
2018年第5期22-25,共4页
Clinical Medication Journal
